CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.

@inproceedings{Mjean2018CARMENACN,
  title={CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.},
  author={Arnaud M{\'e}jean and Bernard Escudier and Simon Th{\'e}z{\'e}nas and J. B. Beauval and Lionnel Geoffroy and Karim Bensalah and Antoine Thiery-vuillemin and L. Sherilyn Cormier and Hauke Lang and Lawrence D. Guy and Gw{\'e}naelle Gravis and Fr{\'e}d{\'e}ric Rolland and Claude Linassier and Marc Olivier Timsit and Laurence K Albiges and Christian Beisland and Michael William Aitchison and S. Navarro Col{\'a}s and Thierry Lebr{\'e}t and Alain Ravaud},
  year={2018}
}
LBA3Background: Cytoreductive nephrectomy (CN) has been the standard of care in mRCC in the past twenty years, supported by randomized and large retrospective studies. However the efficacy of targeted therapies has challenged this standard. CARMENA was designed to answer the question of whether upfront CN should continue to be performed before sunitinib. Methods: CARMENA was a randomized phase III trial. Patients (pts) with synchronous mRCC, amenable to CN, were enrolled after confirmation of… CONTINUE READING